Skip to content Skip to footer
Post 41

Vivos Therapeutics Rebrands Proprietary Clinical Protocol for Treating Patients with Breathing and Sleep Disorders

The Vivos Method’s Proprietary Combination of Multidisciplinary Protocols and Oral Appliances Featured on New Corporate Website HIGHLANDS RANCH Colorado, March 03, 2022 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild…

Read More

Post 39

Vivos Therapeutics to Participate in Upcoming Investor Conferences

Vivos Therapeutics to Participate in Upcoming Investor Conferences HIGHLANDS RANCH Colorado, March 02, 2022 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and…

Read More

Post 40

Vivos Therapeutics to Present at March 2022 World Sleep Congress in Rome

Vivos Medical Advisory Board to Expound on Clinical Data Set of Improved Patient Outcomes at One of the World’s Largest Sleep Conferences HIGHLANDS RANCH Colorado, February 24, 2022 HIGHLANDS RANCH, Colo., Feb. 24, 2022 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic…

Read More

Post 39

Vivos Therapeutics Files for US Patent on Proprietary New Clinical Protocols After Seeing Further Significant Improvement in Reduction of Key Sleep Apnea Metric

Vivos’ Continuous Clinical Improvement Program Yields Promising Data in AHI Score Reductions for Patients with Obstructive Sleep Apnea HIGHLANDS RANCH Colorado, January 27, 2022 Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep…

Read More

Post 38

Vivos Therapeutics Announces 18X Increase in Sleep Apnea Diagnostic Testing By Vivos Dentists Using SleepImage Technology

Vivos Also Announces Improved Pricing Agreement With SleepImage Dentists and Patients Report Exceptional User Experience with SleepImage Home Sleep Test HIGHLANDS RANCH Colorado, January 19, 2022 Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate…

Read More

Post 24

Vivos Therapeutics’ mmRNA Oral Appliance Now Eligible for Medicare Reimbursement

mmRNA is the first and only appliance of its kind covered by Medicare Part of the Vivos System treatment, the mmRNA appliance represents a highly effective, nonsurgical, noninvasive, and nonpharmaceutical alternative for patients suffering from OSA and snoring. HIGHLANDS RANCH Colorado, December 14, 2021 Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology…

Read More

Post 37

Vivos Therapeutics Announces Registration with Health Canada to Manufacture and Sell Sleep-Disorder, Snoring, and Sleep-Apnea Appliances to Canadian Dentists

Vivos management to present at 11:45 am Eastern Time on November 17, 2021 HIGHLANDS RANCH Colorado, December 9, 2021 Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, today…

Read More

Post 36

Vivos Therapeutics Reports Third Quarter 2021 Financial Results and Operational Update

Third Quarter Revenue Increased Over 38% Year-Over-Year Expects to Benefit from Increased OSA Testing, Opening of Live Training Facility, Expansion of Marketing Programs, Additional FDA Approval and Positive Study Results Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH Colorado, November 15, 2021 Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a…

Read More

Post 35

Vivos Therapeutics to Participate at the Q4 Virtual Investor Summit

Vivos management to present at 11:45 am Eastern Time on November 17, 2021 HIGHLANDS RANCH Colorado, November 15, 2021 Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA), today announced that Kirk Huntsman, Chief Executive Officer, Brad…

Read More

Post 34

Vivos Therapeutics Schedules Third Quarter 2021 Financial Results Conference Call

Call Scheduled for Monday, November 15, 2021 at 5:00 pm ET HIGHLANDS RANCH   Colorado, November 9, 2021 Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring in adults,…

Read More